Archive · 19 Jan 2026
Sun Pharma Eyes USD 10 Billion Organon Acquisition
Sun Pharma, a big Indian drug company, is thinking about buying Organon, a US company that specializes in women's healthcare and has a growing biosimilars portfolio.
This deal could be worth around USD 10 billion, including debt.
Organon has been selling some of its assets to reduce its debt, which is currently USD 8.9 billion.
Sun Pharma wants to expand its presence in the US and add more products to its portfolio.
Both companies have strong revenues, with Sun Pharma reporting USD 6.19 billion in FY25 and Organon reporting USD 6.4 billion in FY24.
The deal is still being discussed and may not happen, but if it does, it could be a big change for Sun Pharma.
Sun Pharmaceutical Industries Ltd is evaluating the acquisition of US-based Organon, a women's healthcare specialist with a growing biosimilars portfolio.
The potential deal is estimated at around USD 10 billion, including debt, and would be the largest cross-border acquisition in India's pharmaceutical sector.
Organon has been divesting non-core assets to streamline its balance sheet, with its debt standing at USD 8.9 billion at the end of Q2 2025.
Sun Pharma has a market capitalisation of about USD 45 billion and reported FY25 revenue of Rs 52,041 crore (USD 6.19 billion).
The acquisition could significantly strengthen Sun Pharma's US presence and expand its portfolio, including biosimilars and women's healthcare products.
- Who
- Sun Pharmaceutical Industries Ltd and Organon
- What
- Potential acquisition of Organon by Sun Pharma
- When
- Discussions ongoing, no final agreement yet
- Where
- India and the United States
- Why
- To strengthen Sun Pharma's US presence and expand its portfolio
- Company
- Sun Pharmaceutical Industries Ltd
- Target Company
- Organon
- Estimated Deal Value
- USD 10 billion (including debt)
- Organon's Debt
- USD 8.9 billion (Q2 2025)
- Organon's Market Cap
- USD 2.28 billion
- Sun Pharma's Market Cap
- USD 45 billion
- Sun Pharma's FY25 Revenue
- Rs 52,041 crore (USD 6.19 billion)
- Organon's FY24 Revenue
- USD 6.4 billion
